Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. billion) by 2025. to reach 3.2 billion euros ($3.75 Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

NOVEMBER 1, 2021

billion by 2025 1. Curaleaf International’s cannabis flower products and extracted cannabis-based products now supply five separate markets, including Germany, Europe’s largest market for medicinal cannabis which is expected to be worth over €840 million by 2025 1. billion by 2025 1. billion by 2025 1. billion by 2025 1.

Seed-To-Sale 52

Seed-To-Sale Supply Chain Medicine Research and Development 52

SpeedWeed

JUNE 2, 2021

Of course, new regulations could change things again and again in the coming years, but the data shows the future looks bright for cannabis sales, business growth, patient access, and job growth. In 2025, Marijuana Business Daily projects legal U.S. billion in sales for the craft beer industry in 2025 vs. $45.9

Data 40

Data Media Business Cannabis 40

Cannabis Law Report

JUNE 11, 2019

This first-of-its-kind model bill ends cannabis prohibition, and creates an all-encompassing regulatory framework with an eye towards harmonizing the interests of patients, industry, and the communities most affected by the failure of cannabis prohibition. Economists project that the U.S. ” GACC’s Model U.S.

Legislation 75

Legislation Policy Cannabis Patients 75

Otherside Farms

NOVEMBER 13, 2019

In actuality, experts project that the industry will be worth sixteen billion dollars by the end of 2025. The product, although distasteful to the average Joe, might be a bar of candy for HIV/AIDS and cancer patients. Above all, neurodegeneration, neuronal injury, and psychiatric patients can benefit from consuming CBD.

CBD 53

CBD Chronic Pain Blood Pressure Sleep 53

Cannabis Law Report

SEPTEMBER 22, 2022

SB 1186– Medicinal Cannabis Patients’ Right of Access Act. The bill’s author, Senator Scott Weiner, states this bill is a victory for seniors living with chronic illness, and will both improve patient access and help fill voids throughout the state where no cannabis license types have been authorized.

Law 52

Law Events Packaging Pets 52

Cannabis Law Report

AUGUST 24, 2021

Hoshi will use commercially reasonable efforts to grant Flora access to its European Union Good Manufacturing Practices (“EU-GMP”) auditors for the purposes of assisting Flora to obtain EU-GMP certification at its Cosechemos cultivation and extraction facility in Colombia. billion by 2025. billion by 2025. “We of the market.

Events 105

Events Cultivation Access Business 105

Veriheal

OCTOBER 9, 2020

Mississippi is on the verge of seeing legal access to medical cannabis. Should citizen petition Initiative 65 pass, qualifying patients with one of 22 qualifying conditions would have legal access to cannabis. Early predictions would place sales at around the $193 million mark as early as 2025. Public Question No.1

Legalization 80

Legalization Recreational Retail Programs 80

Cannabis Law Report

SEPTEMBER 27, 2021

According to the New York Department of Health, there were approximately 151,000 certified patients as of September 21, 2021. At the same time, BDS Analytics estimates New York’s illicit cannabis market to reach approximately $5.0 million rentable square feet (including approximately 2.9

Programs 52

Programs Patients Cultivation Dispensary 52

Otherside Farms

SEPTEMBER 13, 2021

In fact, due to its accessibility, the U.S. cannabis industry is projected to reach $30 billion in market value annually by 2025. It’s why many chemotherapy patients rely on this cannabis strain to help with nausea they experience after treatments. Not one cannabis strain is the same. Offers Pain Relief.

Indica 52

Indica Sativa Strains Terpenes 52

Veriheal

JUNE 21, 2023

There will also be measures put in place to control therapeutic access to psilocybin while awaiting federal reform. If approved by the Food and Drug Administration (FDA), this psychedelic would be used to treat chronic and life-threatening mental disorders, especially for patients with limited access to effective treatments.

Access 97

Access Legalization Research and Development Legislation 97

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The patent will be issued on January 11, 2022. President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. The market for treating aging disorders and extending healthy lifespan is expected to be at least $600 billion by 2025 1 according to a major investment bank.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 9, 2022

The state’s medical patients (about 0.5% Vermont’s law requires that cannabis tax revenue be “used to fund a grant program to start or expand afterschool and summer learning programs, with a focus on increasing access in underserved areas.”. Those sales were taxed at 25% beginning January 4, 2016. Arizona (pop. New Mexico (pop.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

AUGUST 9, 2021

Currently, the common methods of use for medical cannabis are by inhalation of smoke or vapor, or sublingual drops, and many patients are reluctant to use cannabis due to these methods. The patent approval is significant for the medical cannabis market. Of Cannassure.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Cannabis Law Report

SEPTEMBER 21, 2022

The continued strength of the Company’s medical adjusted gross margins 1 reflect the direct-to-patient model in Canada and sustained presence in the high margin international medical business. As of June 30, 2022 , the Company has access to US$713.7 million under the ATM Program.

Research and Development 52

Research and Development Cannabis Data Events 52

Cannabis Law Report

AUGUST 31, 2021

As part of the pre-launch, G-nnovation products will be marketed in Israel to a limited number of licensed patients through Telepharma pharmacy, with whom Canonic recently engaged. According to industry estimates, based on current growth rates, the Israeli market will reach approximately 250,000 patients by 2025.[4].

Seed-To-Sale 102

Seed-To-Sale Patients Agriculture Cannabis 102

Veriheal

JANUARY 26, 2024

Another new proposal, and an innovative one, would allow patients over 65 years old to self-certify for medicinal marijuana without the recommendation of a physician. It would also allow patients with terminal illnesses to receive cards with no expiration dates.

Access 105

Access Legalization Marijuana Dispensary 105

Cannabis Law Report

OCTOBER 19, 2021

Canonic moves ahead of schedule with the full commercial launch of its G-nnovation products, following positive feedback from patients during the company’s pre-launch campaign. According to industry estimates, based on current growth rates, the number of patients in the Israeli market is expected to more than double by 2025 [7].

Patients 52

Patients Cannabis Programs Access 52

Cannabis Law Report

JULY 15, 2022

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

Medicine 52

Medicine Patients Media Supply Chain 52

SMPL

MAY 26, 2020

Miller spent the months after this meeting leading hundreds of CBD seminars for farmers; Dr. Kerr began informal patient surveys to track how CBD made people feel; and as he finished his book, Mr. Lee often traveled around with Mr. Laughter and Mr. Ringo’s high-CBD plants and seeds, spreading the gospel at pot shops across the West.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

JUNE 7, 2021

According to Prohibition Partners, active patients grew by approximately 17% from 2019 to 2020, reaching over 70,000 patients, leading to imports into Israel of over 7 tonnes by July 2020. 230 million by 2025. “We The Israeli medical cannabis market was characterized by strong year-over-year growth in 2020. d/b/a “ JWC ”).

Cultivation 100

Cultivation Recreational Cannabis Events 100

Cannabis Law Report

JUNE 17, 2021

We empower cultivators and offer them fast-tracked, secure European market access, while helping them grow their brand”, Philip Schetter , Co-CEO of Cantourage, comments. Our platform expands and enhances the offering to patients and healthcare providers in Europe , in terms of both product and pricing.

Cultivation 94

Cultivation Access Extraction Patients 94

SpeedWeed

MARCH 15, 2021

That move made it easier for patients to obtain medical cards. For all the positive change with consumers and revenue-starved state officials, serious obstacles remain – lack of banking access, federal prohibition and medical-establishment skepticism, among others. Help at the state and federal levels. 1, 2024, start.

Marijuana 52

Marijuana Banking Recreational Programs 52

SpeedWeed

SEPTEMBER 8, 2021

Our focus on delivering high quality products that meet the needs and wants of our patients and customers is one of our biggest priorities as Curaleaf continues to scale,” said CEO Joe Bayern in an email to CBT and CD. “We Others said investor demand for access to the industry could be a catalyst for financial reform. What Comes Next?

Seed-To-Sale 52

Seed-To-Sale Banking Legislation Education 52

SpeedWeed

SEPTEMBER 8, 2021

Our focus on delivering high quality products that meet the needs and wants of our patients and customers is one of our biggest priorities as Curaleaf continues to scale,” said CEO Joe Bayern in an email to CBT and CD. “We Others said investor demand for access to the industry could be a catalyst for financial reform. What Comes Next?

Seed-To-Sale 52

Seed-To-Sale Banking Legislation Education 52

SpeedWeed

SEPTEMBER 9, 2021

Our focus on delivering high quality products that meet the needs and wants of our patients and customers is one of our biggest priorities as Curaleaf continues to scale,” said CEO Joe Bayern in an email to CBT and CD. “We Others said investor demand for access to the industry could be a catalyst for financial reform. What Comes Next?

Seed-To-Sale 52

Seed-To-Sale Banking Legislation Education 52

Cannabis Law Report

OCTOBER 17, 2019

billion in 2025, according to Grandview Research. It’s big business,” says Jackim, noting that there are 200,000 patients in the state who hold cards allowing them to purchase cannabis for medical purposes. billion in 2018, and with a compound annual growth rate of 23.9%, is predicted to reach $66.3

Law 40

Law Seed-To-Sale Hemp Recreational 40